{
  "norepinephrine": {
    "genericName": "Norepinephrine",
    "brandName": "Levophed",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Predominantly α-receptor–mediated vasoconstriction with weak β-receptor agonism producing modest cardiac stimulation; usual doses do not appear to impair renal function.",
    "indications": [
      "Preferred vasopressor in septic shock",
      "Vasodilatory shock requiring vasopressor support"
    ],
    "commonDosing": [
      "Start 5–10 μg/min IV infusion; titrate upward to effect",
      "β-receptor stimulation may increase cardiac output at <10 μg/min",
      "α-mediated vasoconstriction predominates at >10 μg/min",
      "Around 30 μg/min, further increases seldom add effect; consider adding a second vasopressor"
    ],
    "adverseEffects": [
      "Ischemic events (myocardial, cerebral, limb)",
      "Troublesome arrhythmias (tachycardia, bradycardia)",
      "Serious events reported in ~10% of patients, though many may reflect underlying shock"
    ],
    "monitoring": [
      "MAP/arterial blood pressure",
      "Heart rate and rhythm",
      "Signs of ischemia (cardiac, neurologic, limb)",
      "Urine output and peripheral perfusion"
    ],
    "contraindications": "",
    "cautions": "",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "vasopressin": {
    "genericName": "Vasopressin",
    "brandName": "Pitressin",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "V1 receptor–mediated vasoconstriction (arterial); V2 antidiuretic effect.",
    "indications": [
      "Septic shock resistant to norepinephrine (e.g., ≥0.2 μg/kg/min) as an adjunct (catecholamine-sparing; no proven survival benefit)",
      "Cardiac arrest: single IV dose of 40 units may replace the first or second epinephrine dose"
    ],
    "commonDosing": [
      "Septic shock: continuous infusion 0.03–0.04 Units/hr; not titrated (unlike catecholamine vasopressors)"
    ],
    "adverseEffects": [
      "Similar in type and frequency to norepinephrine",
      "Ischemic events",
      "Arrhythmias"
    ],
    "monitoring": [
      "MAP/arterial blood pressure and perfusion",
      "Cardiac rhythm",
      "Clinical signs of ischemia"
    ],
    "contraindications": "",
    "cautions": "Used as an adjunct when norepinephrine support is inadequate; catecholamine-sparing effect noted; no demonstrated survival benefit in septic shock.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },
  
  "epinephrine": {
    "genericName": "Epinephrine",
    "brandName": "Bosmin",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Potent β-receptor agonist producing dose-dependent increases in heart rate, stroke volume, and blood pressure; also exerts α-receptor–mediated vasoconstriction.",
    "indications": [
      "Cardiopulmonary resuscitation (first-line vasopressor)",
      "Anaphylactic shock resuscitation",
      "Third-line vasopressor in septic shock when hypotension remains refractory to norepinephrine ± vasopressin"
    ],
    "commonDosing": [
      "Septic shock: continuous infusion, start 0.1 μg/kg/min IV; titrate upward as needed; maximum 0.5 μg/kg/min",
      "CPR and anaphylaxis doses as per advanced life support and anaphylaxis protocols (see respective guidelines/chapters)"
    ],
    "adverseEffects": [
      "Unwanted cardiac stimulation (tachycardia, arrhythmias)",
      "Splanchnic hypoperfusion from α-mediated vasoconstriction (risk of mucosal barrier damage)",
      "Increased metabolic rate (counterproductive in shock)",
      "Hyperglycemia (α-mediated inhibition of insulin secretion)",
      "Increased plasma lactate (from enhanced aerobic lactate production), which may be misleading in shock"
    ],
    "monitoring": [
      "MAP/arterial blood pressure",
      "Heart rate and rhythm",
      "Signs of gut or peripheral ischemia",
      "Serum glucose",
      "Serum lactate (interpret with caution)"
    ],
    "contraindications": "",
    "cautions": "At this institution, epinephrine is considered a third-line vasopressor in septic shock; metabolic and ischemic side effects limit its routine use. Interpret lactate cautiously when using epinephrine.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },
  
  "dopamine": {
    "genericName": "Dopamine",
    "brandName": "Dopamine",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Endogenous catecholamine and precursor of norepinephrine; exhibits dose-dependent effects: ≤3 μg/kg/min activates dopamine receptors (renal, splanchnic vasodilation); 3–10 μg/kg/min stimulates β-receptors (↑stroke volume, cardiac output); >10 μg/kg/min activates α-receptors (vasoconstriction, ↑SVR, ↑afterload).",
    "indications": [
      "Previously used as a vasopressor in septic shock (now largely replaced by norepinephrine)",
      "Occasional use in cardiogenic shock with low cardiac output and bradycardia when norepinephrine is not suitable"
    ],
    "commonDosing": [
      "Start at 5 μg/kg/min IV infusion; titrate upward as needed",
      "5–10 μg/kg/min: usually increases cardiac output",
      ">10 μg/kg/min: vasoconstriction and BP increase",
      "Reported use up to 20–50 μg/kg/min, though higher doses increase adverse effects"
    ],
    "adverseEffects": [
      "Tachycardia and troublesome tachyarrhythmias (e.g., atrial fibrillation), more frequent than with other vasopressors",
      "Increased intraocular pressure reported even at low doses (1–4 μg/kg/min)",
      "Excessive vasoconstriction and ↑afterload at high doses"
    ],
    "monitoring": [
      "MAP/arterial blood pressure",
      "Heart rate and rhythm (arrhythmia surveillance)",
      "Signs of ischemia (cardiac, peripheral)",
      "Ocular pressure if clinically relevant"
    ],
    "contraindications": "",
    "cautions": "Fallen out of favor as first-line therapy in septic shock due to higher risk of tachyarrhythmias; benefits are dose-dependent but limited by adverse effects.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },
  
  "propofol": {
    "genericName": "Propofol",
    "brandName": "Fresofol",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Rapidly acting GABAergic sedative; produces sedation, amnesia, and anticonvulsant effects without analgesia.",
    "indications": [
      "Induction of general anesthesia",
      "Sedation during mechanical ventilation in ICU patients",
      "Procedural sedation"
    ],
    "commonDosing": [
      "Bolus: produces sedation within 1–2 minutes, lasting 5–8 minutes (not recommended in hemodynamically unstable patients)",
      "Continuous infusion: titrate to maintain light sedation when possible",
      "High doses (>80 μg/kg/min or >5 mg/kg/hr for >48h) associated with propofol infusion syndrome (PRIS)"
    ],
    "adverseEffects": [
      "Respiratory depression (requires mechanical ventilation support)",
      "Hypotension due to systemic vasodilation (especially in hypovolemia or heart failure)",
      "Hypertriglyceridemia (from lipid emulsion vehicle)",
      "Necrotizing pancreatitis (rare)",
      "Anaphylactoid reactions (uncommon)",
      "Green urine discoloration (benign metabolite effect)",
      "Propofol Infusion Syndrome (heart failure, lactic acidosis, rhabdomyolysis, renal failure, multiorgan failure; 30–35% mortality)"
    ],
    "monitoring": [
      "Airway and ventilatory status",
      "Blood pressure and hemodynamic status",
      "Sedation depth (light vs deep sedation goals)",
      "Serum triglycerides during prolonged infusion",
      "Laboratory markers of metabolic acidosis, CK, renal function for early signs of PRIS"
    ],
    "contraindications": "",
    "cautions": "Avoid loading doses in hemodynamically unstable patients; maintain light sedation to minimize delayed arousal; account for lipid calories (1 kcal/mL) in daily nutrition; monitor closely for PRIS when using prolonged high-dose infusions.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },
  
  "dexmedetomidine": {
    "genericName": "Dexmedetomidine",
    "brandName": "Precedex",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Selective α2-adrenergic agonist producing sedation, amnesia, and mild analgesia without ventilatory depression; sedation resembles natural sleep.",
    "indications": [
      "Sedation of mechanically ventilated ICU patients (preferred over benzodiazepines)",
      "Situations requiring cooperative sedation (e.g., ventilator weaning, neurological evaluations in stroke/TBI)",
      "Treatment of ICU-related delirium (drug of choice)",
      "Procedural sedation in non-intubated patients"
    ],
    "commonDosing": [
      "Loading dose: 1 μg/kg IV over 10 minutes (often omitted in ICU due to risk of hypotension/bradycardia)",
      "Maintenance infusion: 0.2–0.7 μg/kg/hr (may increase up to 1.5 μg/kg/hr per institutional protocols)",
      "No need for daily sedation interruption due to cooperative sedation profile"
    ],
    "adverseEffects": [
      "Dose-dependent bradycardia and hypotension (sympatholytic effect)",
      "Marked hemodynamic depression in conditions dependent on sympathetic tone (e.g., HFrEF)",
      "Withdrawal syndrome with sympathetic overactivity (tachycardia, hypertension, agitation) in ~30% of patients, unrelated to dose or duration"
    ],
    "monitoring": [
      "Heart rate and rhythm",
      "Blood pressure and perfusion",
      "Sedation depth (RASS or equivalent)",
      "Signs of withdrawal upon discontinuation"
    ],
    "contraindications": "",
    "cautions": "Avoid loading dose in hemodynamically unstable patients; anticipate bradycardia and hypotension; monitor for withdrawal syndrome; use with caution in advanced heart failure with reduced ejection fraction.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },
  
  "midazolam": {
    "genericName": "Midazolam",
    "brandName": "Dormicum",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Short-acting benzodiazepine; enhances GABA-A receptor activity to produce sedation, anxiolysis, amnesia, and anticonvulsant effects.",
    "indications": [
      "Procedural sedation (favored agent)",
      "Short-term sedation in ICU patients",
      "Adjunct in management of seizures or agitation"
    ],
    "commonDosing": [
      "Bolus: sedation within 5 minutes, lasting 1–2 hours",
      "Continuous infusion for prolonged sedation (limit to ≤48 hours to reduce risk of drug accumulation)",
      "Metabolized by hepatic CYP450 system; interactions with enzyme inhibitors (e.g., diltiazem, erythromycin) can potentiate effect"
    ],
    "adverseEffects": [
      "Respiratory depression",
      "Hypotension",
      "Drug accumulation and prolonged sedation with continuous infusion (especially >48h)",
      "Prolonged effect with hepatic impairment or renal impairment (due to active metabolite)"
    ],
    "monitoring": [
      "Airway and ventilatory status",
      "Hemodynamics",
      "Sedation depth (RASS or equivalent)",
      "Renal and hepatic function for risk of accumulation",
      "Drug interactions with CYP450 inhibitors"
    ],
    "contraindications": "",
    "cautions": "Avoid prolonged continuous infusions due to drug accumulation and delayed awakening; higher risk of ICU-related delirium compared to non-benzodiazepine sedatives.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "lorazepam": {
    "genericName": "Lorazepam",
    "brandName": "Anxicam",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Intermediate-acting benzodiazepine; enhances GABA-A receptor activity, producing sedation, anxiolysis, amnesia, and anticonvulsant effects.",
    "indications": [
      "Continuous sedation in ICU patients (preferred benzodiazepine for prolonged infusion)",
      "Management of anxiety and agitation",
      "Treatment of alcohol or opioid withdrawal",
      "Adjunct in seizure control"
    ],
    "commonDosing": [
      "Bolus: rapid onset, effect lasting up to 6 hours",
      "Continuous infusion: 0.01–0.1 mg/kg/hr; risk of propylene glycol toxicity if infusion >10 mg/hr or >0.1 mg/kg/hr beyond 48h"
    ],
    "adverseEffects": [
      "Respiratory depression",
      "Hypotension",
      "Prolonged sedation and delayed awakening (less pronounced than midazolam)",
      "Propylene glycol toxicity: metabolic acidosis, altered mentation, systemic inflammation, renal failure"
    ],
    "monitoring": [
      "Airway and ventilatory status",
      "Hemodynamics",
      "Sedation depth (RASS or equivalent)",
      "Osmolal gap (>10 mOsm/kg H2O suggests propylene glycol accumulation)",
      "Renal and hepatic function"
    ],
    "contraindications": "",
    "cautions": "Avoid high-dose or prolonged infusion due to risk of propylene glycol toxicity; monitor osmolal gap if infusion ≥0.1 mg/kg/hr or >10 mg/hr for >48h; associated with increased risk of ICU-related delirium compared with non-benzodiazepine sedatives.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "fentanyl": {
    "genericName": "Fentanyl",
    "brandName": "Fentanyl",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Synthetic μ-opioid receptor agonist; highly lipophilic, rapid onset; lacks histamine release compared with morphine.",
    "indications": [
      "Preferred opioid analgesic in ICUs",
      "Analgesia for mechanically ventilated patients",
      "Adjunct to sedation and procedural analgesia"
    ],
    "commonDosing": [
      "IV bolus: onset rapid; titrate to effect",
      "Continuous infusion: individualized dosing for ICU analgesia",
      "Note: drug can accumulate in CNS with prolonged use"
    ],
    "adverseEffects": [
      "Respiratory depression",
      "Sedation and CNS accumulation with prolonged infusion",
      "Bradycardia, chest wall rigidity (with rapid high-dose administration)",
      "Possible accumulation in renal failure despite no active metabolites"
    ],
    "monitoring": [
      "Respiratory rate and oxygenation",
      "Hemodynamic stability",
      "Analgesia and sedation depth",
      "Accumulation risk in renal dysfunction"
    ],
    "contraindications": "",
    "cautions": "Although fentanyl has no active metabolites, the parent drug may accumulate in renal failure; some recommend avoiding use in end-stage renal disease.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "morphine": {
    "genericName": "Morphine",
    "brandName": "Morphine",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Principal alkaloid of opium; μ-opioid receptor agonist with active metabolites that contribute to both analgesia and toxicity.",
    "indications": [
      "Traditional opioid analgesic for ICU pain control",
      "Alternative to fentanyl when cost or availability is a concern"
    ],
    "commonDosing": [
      "IV bolus or continuous infusion titrated to effect",
      "Maintenance dose should be reduced by 50% in patients with renal failure due to metabolite accumulation"
    ],
    "adverseEffects": [
      "Active metabolite accumulation in renal failure",
      "Morphine-3-glucuronide: neurotoxic (myoclonus, seizures, agitation)",
      "Morphine-6-glucuronide: potent analgesic metabolite",
      "Histamine release → systemic vasodilation and hypotension"
    ],
    "monitoring": [
      "Respiratory rate and oxygenation",
      "Hemodynamics (risk of hypotension from histamine release)",
      "Renal function to adjust maintenance dose",
      "Neurological status for signs of metabolite toxicity"
    ],
    "contraindications": "",
    "cautions": "Use with caution in renal failure; reduce dose to avoid metabolite accumulation. Histamine release may cause hypotension, especially in hyperadrenergic states. Does not cause bronchospasm despite histamine release.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "succinylcholine": {
    "genericName": "Succinylcholine",
    "brandName": "Relaxin",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Depolarizing neuromuscular blocker; binds to acetylcholine receptors, causing sustained depolarization and flaccid paralysis.",
    "indications": [
      "Rapid-sequence endotracheal intubation (RSI)",
      "Situations requiring rapid onset and short duration of paralysis"
    ],
    "commonDosing": [
      "IV bolus: 1.0 mg/kg for RSI",
      "Onset: 60–90 seconds; Duration: 7–12 minutes"
    ],
    "adverseEffects": [
      "Hyperkalemia (↑serum K+ up to 0.5 mEq/L, life-threatening in burns, rhabdomyolysis, SCI, malignant hyperthermia)",
      "Contraindicated in patients with hyperkalemia or risk factors for potassium efflux",
      "Malignant hyperthermia trigger",
      "Fasciculations and myalgias"
    ],
    "monitoring": [
      "Neuromuscular function (TOF when infusion or repeated doses)",
      "Serum potassium in at-risk patients"
    ],
    "contraindications": "Hyperkalemia, malignant hyperthermia, rhabdomyolysis, severe burns, spinal cord injury with immobility",
    "cautions": "Use only when rapid intubation is required and contraindications are excluded.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "rocuronium": {
    "genericName": "Rocuronium",
    "brandName": "Rocuronium",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Non-depolarizing aminosteroid neuromuscular blocker; competitively inhibits acetylcholine binding at nicotinic receptors.",
    "indications": [
      "Endotracheal intubation when succinylcholine is contraindicated",
      "Facilitation of mechanical ventilation",
      "Adjunct during procedures requiring paralysis"
    ],
    "commonDosing": [
      "IV bolus: 1.0 mg/kg for intubation (onset ≈ 1.5–3 min, comparable to succinylcholine)",
      "Maintenance: infusion titrated to TOF monitoring",
      "Duration: 30–70 minutes (intermediate)"
    ],
    "adverseEffects": [
      "Prolonged duration of paralysis (especially with hepatic dysfunction)",
      "Risk of residual paralysis if not reversed",
      "Rare anaphylaxis"
    ],
    "monitoring": [
      "Train-of-four (TOF) stimulation, target 1–2/4 twitches",
      "Adequate sedation and analgesia during paralysis",
      "Hemodynamic status"
    ],
    "contraindications": "",
    "cautions": "Longer duration than succinylcholine may complicate failed airway; reversal with sugammadex (16 mg/kg for immediate reversal) available.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "cisatracurium": {
    "genericName": "Cisatracurium",
    "brandName": "Nimbex",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Non-depolarizing benzylisoquinolinium neuromuscular blocker; competitively inhibits acetylcholine receptors; eliminated by Hofmann degradation (organ-independent).",
    "indications": [
      "ICU paralysis for ventilator synchrony in ARDS or severe hypoxemia",
      "Prevention of shivering during induced hypothermia",
      "Adjunct to control intracranial pressure or facilitate procedures"
    ],
    "commonDosing": [
      "Onset: 5–7 minutes; Duration: 35–50 minutes (intermediate)",
      "Infusion titrated to TOF monitoring"
    ],
    "adverseEffects": [
      "Prolonged paralysis and weakness with prolonged infusion",
      "Critical illness myopathy (with steroids/neuromuscular blockers)",
      "Minimal histamine release (unlike atracurium)"
    ],
    "monitoring": [
      "Train-of-four (TOF) target 1–2/4 twitches",
      "Adequate analgesia and sedation (patients may be awake while paralyzed)",
      "Eye care, pressure ulcer prevention, DVT prophylaxis"
    ],
    "contraindications": "",
    "cautions": "Elimination independent of renal or hepatic function; useful in organ failure. Avoid prolonged paralysis due to risk of ICU-acquired weakness.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "neostigmine": {
    "genericName": "Neostigmine",
    "brandName": "Neostigmine",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Acetylcholinesterase inhibitor; increases acetylcholine levels at neuromuscular junction, overcoming competitive blockade by non-depolarizing agents.",
    "indications": [
      "Reversal of non-depolarizing neuromuscular blockade (e.g., rocuronium, cisatracurium, vecuronium)"
    ],
    "commonDosing": [
      "IV 70 μg/kg (max dose), typically with an anticholinergic (e.g., glycopyrrolate) to reduce muscarinic side effects",
      "Reversal time varies 8–45 minutes depending on depth of block and anesthetic agents"
    ],
    "adverseEffects": [
      "Parasympathomimetic effects: bradycardia, bronchospasm, salivation, GI upset",
      "Incomplete or delayed reversal if deep block",
      "Risk of muscarinic side effects if not co-administered with anticholinergic agent"
    ],
    "monitoring": [
      "Train-of-four (TOF) monitoring for adequacy of reversal",
      "Heart rate and rhythm during administration",
      "Signs of cholinergic excess"
    ],
    "contraindications": "",
    "cautions": "Do not exceed 70 μg/kg due to risk of muscarinic toxicity; reversal slower and less predictable than sugammadex.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "sugammadex": {
    "genericName": "Sugammadex",
    "brandName": "Sugammadex",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Selective relaxant binding agent; encapsulates aminosteroid neuromuscular blockers (especially rocuronium, vecuronium), removing them from the neuromuscular junction.",
    "indications": [
      "Rapid reversal of rocuronium- or vecuronium-induced neuromuscular blockade",
      "Rescue reversal in failed airway scenarios after rocuronium"
    ],
    "commonDosing": [
      "16 mg/kg IV for immediate reversal (e.g., failed intubation rescue) — onset 2–3 minutes",
      "4 mg/kg IV for deep blockade",
      "2 mg/kg IV for moderate blockade",
      "Reversal is consistently faster than neostigmine, without muscarinic side effects"
    ],
    "adverseEffects": [
      "Hypersensitivity reactions (rare)",
      "Bradycardia (rare, but reported)",
      "Cost considerations compared with neostigmine"
    ],
    "monitoring": [
      "Train-of-four (TOF) monitoring",
      "Heart rate and rhythm after administration",
      "Clinical recovery of muscle strength"
    ],
    "contraindications": "",
    "cautions": "Binds only aminosteroid neuromuscular blockers (rocuronium, vecuronium, pancuronium); not effective against benzylisoquinolinium agents like cisatracurium.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "amiodarone": {
    "genericName": "Amiodarone",
    "brandName": "Cordarone",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Class III antiarrhythmic with multiple channel-blocking properties (Na, K, Ca) and non-competitive β-blockade; effective in rate control and rhythm conversion.",
    "indications": [
      "Alternative to diltiazem or beta blockers in atrial fibrillation/flutter when resistant or intolerant",
      "Favored in patients with heart failure and reduced ejection fraction (less cardiac depression)",
      "Conversion of atrial fibrillation to sinus rhythm (variable efficacy)",
      "Management of ventricular tachyarrhythmias"
    ],
    "commonDosing": [
      "IV: total loading ≈ 1 g over first 24h (e.g., 150 mg IV over 10 min, then 1 mg/min for 6h, then 0.5 mg/min for 18h)",
      "Transition to PO: start 400 mg PO 4–5h before stopping infusion; continue 400 mg PO BID until total loading dose (IV+PO) ≈ 10 g",
      "Maintenance: 100–200 mg PO daily"
    ],
    "adverseEffects": [
      "Hypotension (mostly solvent-related with IV polysorbate 80 formulation)",
      "QT prolongation and rare torsades de pointes",
      "Drug interactions via CYP450 inhibition (notably ↑digoxin and ↑warfarin levels)",
      "Long-term toxicities (e.g., pulmonary fibrosis, thyroid dysfunction) not seen with short-term IV use"
    ],
    "monitoring": [
      "Blood pressure and rhythm during infusion",
      "QT interval on ECG",
      "Serum digoxin and INR if concomitant therapy",
      "Transitioning regimen to oral dosing"
    ],
    "contraindications": "",
    "cautions": "IV hypotension is formulation-related (solvent); aqueous formulations reduce this risk. Use caution with concomitant digoxin or warfarin (requires dose adjustment and monitoring).",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "nitroglycerin": {
    "genericName": "Nitroglycerin",
    "brandName": "NTG",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Organic nitrate; venodilator and arterial vasodilator via nitric oxide–mediated smooth muscle relaxation; reduces preload and afterload, improving myocardial oxygen balance.",
    "indications": [
      "Relief of angina pectoris (sublingual tablet or spray)",
      "Adjunct in acute coronary syndrome (ACS) with hypertension or decompensated heart failure",
      "Vasodilator of choice for hypertensive acute heart failure"
    ],
    "commonDosing": [
      "Sublingual: 0.3–0.6 mg q5min PRN for chest pain, up to 3 doses in 15 minutes",
      "IV infusion: start at 5 μg/min, increase by 5 μg/min every 5 min to effect",
      "Usual effective dose: 5–100 μg/min; avoid >200 μg/min",
      "Avoid infusion beyond 24h (tachyphylaxis common)"
    ],
    "adverseEffects": [
      "Hypotension",
      "Headache",
      "Tachyphylaxis after 24h continuous infusion",
      "Propylene glycol toxicity with prolonged infusion (lactic acidosis, delirium, hypotension, multiorgan failure)",
      "Methemoglobinemia with very high doses"
    ],
    "monitoring": [
      "Blood pressure and heart rate",
      "Clinical response (angina relief, hemodynamics in HF/ACS)",
      "Signs of tachyphylaxis after 24h",
      "Methemoglobin level if unexplained hypoxemia during very high dosing"
    ],
    "contraindications": "Right ventricular infarction, severe aortic stenosis, concurrent use of phosphodiesterase-5 inhibitors within past 24–48h",
    "cautions": "Drug adsorbs to PVC tubing and bags, causing up to 80% loss; use glass bottles and polyethylene tubing. Avoid prolonged infusion (>24h) due to tachyphylaxis and solvent toxicity.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  },

  "nicardipine": {
    "genericName": "Nicardipine",
    "brandName": "Perdipine",
    "lastReviewed": "2025-09-18",
    "mechanismOfAction": "Calcium channel blocker (dihydropyridine class); arterial vasodilator that reduces systemic vascular resistance and blood pressure.",
    "indications": [
      "IV antihypertensive therapy in ICU",
      "Adjunct in acute aortic dissection (only in combination with a β-blocker to prevent reflex tachycardia and increased shear stress)"
    ],
    "commonDosing": [
      "Start infusion at 5 mg/hr",
      "Increase by 2.5 mg/hr every 5 min as needed",
      "Maximum dose: 15 mg/hr",
      "Always combine with a β-blocker (e.g., esmolol) in aortic dissection"
    ],
    "adverseEffects": [
      "Reflex tachycardia (if used without β-blocker)",
      "Hypotension",
      "Headache, flushing"
    ],
    "monitoring": [
      "Blood pressure (goal systolic ≈ 120 mmHg in aortic dissection, tolerance down to 90 mmHg)",
      "Heart rate (avoid reflex tachycardia)",
      "Signs of end-organ perfusion"
    ],
    "contraindications": "",
    "cautions": "Must be combined with β-blocker in aortic dissection to avoid reflex tachycardia and increased shear forces. Not a substitute for definitive surgical repair in type A dissection.",
    "sources": [
      { "label": "Marino PL. The ICU Book, 5th ed." }
    ]
  }

}